Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass
Use of argatroban as an alternative to heparin during cardiopulmonary bypass (CPB) in patients with heparin-induced thrombocytopenia has gained some attention in the past two decades. Dosing of argatroban during CPB is complex due to lack of complete understanding of its pharmacokinetic profile and...
Main Authors: | Shvetank Agarwal, Beth Ullom, Yasser Al-Baghdadi, Michael Okumura |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2012-01-01
|
Series: | Journal of Anaesthesiology Clinical Pharmacology |
Subjects: | |
Online Access: | http://www.joacp.org/article.asp?issn=0970-9185;year=2012;volume=28;issue=1;spage=106;epage=110;aulast=Agarwal |
Similar Items
-
Argatroban for an alternative anticoagulant in HIT during ECMO
by: Alain Rougé, et al.
Published: (2017-06-01) -
Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry – a prospectively controlled randomized double-blind clinical trial
by: Martin Beiderlinden, et al.
Published: (2018-02-01) -
Off-pump coronary artery bypass with heparin in a patient with a history of heparin-induced thrombocytopenia: a case report
by: Yuya Ito, et al.
Published: (2021-12-01) -
Massive Left Atrial Thrombus in Two Patients with Heparin-Induced Thrombocytopenia Type II after Cardiac Surgery
by: Yuriy Mandryk, et al.
Published: (2018-07-01) -
Risk Factors Associated with Difficult Reversal of Heparin by Protamine Sulfate in Cardiopulmonary Bypass: An Ignored Issue
by: Min Jung Ku, et al.
Published: (2020-10-01)